- Verified Reactivity
- Human
- Reported Reactivity
- Chimpanzee
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
- Application Notes
Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 302267 & 302268).
?
Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing
- Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Bradbury L, et al. 1993. J. Immunol. 151:2915.
- Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
- Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
- Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
- Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
- Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
- Product Citations
-
- Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
- Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
- Ivan Jelcic et al. 2018. Cell. 175(1):85-100 . PubMed
- Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
- Munteanu AN, et al. 2019. Exp Ther Med. 18:1693. PubMed
- Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed
- Palamides P, et al. 2016. Dis Model Mech. 9: 985 - 997. PubMed
- Sung BY, et al. 2022. J Clin Invest. 132:. PubMed
- R?lle A, et al. 2018. Cell Rep. 24:1967. PubMed
- Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
- Walk J, et al. 2019. Nat Commun. 10:874. PubMed
- Japp AS, et al. 2021. Cell. 184(3):827-839.e14. PubMed
- Ramendra R, et al. 2021. Front Immunol. 12:694152. PubMed
- Rice TF, et al. 2021. EBioMedicine. 72:103612. PubMed
- Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
- Lerrer S, et al. 2021. iScience. 24:103020. PubMed
- Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed
- He WT, et al. 2022. Nat Immunol. 23:960. PubMed
- Huang N, et al. 2020. Genome Biol. 1.03125. PubMed
- Zumaquero E, et al. 2019. Elife. 8. PubMed
- Gawel DR, et al. 2019. Genome Med. 11:47. PubMed
- Garcia-Carmona Y, et al. 2015. Blood. 125:1749. PubMed
- Lima J, et al. 2016. Reprod Sci. 10.1177/1933719116653680. PubMed
- Graham C, et al. 2021. Immunity. 54(6):1276-1289.e6. PubMed
- Seow J, et al. 2022. Cell Rep. 39:110757. PubMed
- Lev A, et al. 2021. J Exp Med. 218:. PubMed
- K?rner C et al. 2017. Cell host & microbe. 22(1):111-119 . PubMed
- Adhikaree J, et al. 2019. Oncoimmunology. 8:1593803. PubMed
- Calzoni E, et al. 2019. J Allergy Clin Immunol. 143:2317. PubMed
- Motozono C, et al. 2021. Cell Host Microbe. . PubMed
- Abolhalaj M, et al. 2022. Cancer Med. 11:3023. PubMed
- Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
- Inui M, et al. 2015. Int Immunol. 27: 345 - 355. PubMed
- Fraser H, et al. 2015. J Immunol. 195: 4841 - 4852. PubMed
- Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
- Sweeney CL, et al. 2021. Gene Ther. 28:373. PubMed
- Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
- Teirlinck A, et al. 2015. Infect Immun . 83: 3732-3739. PubMed
- Duncan CJA, et al. 2022. J Exp Med. 219:. PubMed
- Sullivan KD et al. 2016. eLife. 5 pii: e16220. PubMed
- Li M, et al. 2020. Nat Commun. 4051:11. PubMed
- Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
- Lubaki N, et al. 2016. PLoS Pathog. 12:e1006031. PubMed
- Lepore M, et al. 2014. J Exp Med. 211:1363. PubMed
- RRID
- AB_2275547 (BioLegend Cat. No. 302229) AB_2073119 (BioLegend Cat. No. 302230)
